SAREPTA THERAPEUTICS INC

NASDAQ: SRPT (Sarepta Therapeutics, Inc.)

最近更新时间: 13小时之前

22.16

0.05 (0.23%)

  • 1天 0.23%
  • 5天 -4.73%
  • 1月 26.85%
  • 6月 -59.44%
  • 今年至今天 -82.14%
  • 1年 -82.18%
  • 5年 -84.73%
前收盘价格 22.11
收盘价格 22.00
成交量 3,334,958
平均成交量 (3个月) 12,379,912
市值 2,319,529,984
预期市盈率 (P/E Forward) 8.67
价格/销量 (P/S) 0.990
股市价格/股市净资产 (P/B) 1.72
52周波幅
10.42 (-52%) — 138.81 (526%)
利润日期 5 Nov 2025
营业毛利率 -11.12%
营业利益率 (TTM) -40.33%
稀释每股收益 (EPS TTM) -2.64
季度收入增长率 (YOY) 80.20%
季度盈利增长率 (YOY) 248.40%
总债务/股东权益 (D/E MRQ) 118.73%
流动比率 (MRQ) 4.02
营业现金流 (OCF TTM) -547.15 M
杠杆自由现金流 (LFCF TTM) -741.26 M
资产报酬率 (ROA TTM) -2.19%
股东权益报酬率 (ROE TTM) -23.61%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 Sarepta Therapeutics, Inc. 看跌 看跌

AIStockmoo 评分

-0.3
分析师共识 -3.5
内部交易活动 NA
价格波动 0.5
技术平均移动指标 0.0
技术振荡指标 2.0
平均 -0.25

相关股票

股票 市值 DY P/E（TTM） P/B
SRPT 2 B - - 1.72
RVMD 9 B - - 4.58
PTCT 5 B - 9.06 -
CRNX 4 B - - 3.34
OCUL 2 B - - 7.66
IDYA 2 B - - 2.48

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
部门 Healthcare
行业 Biotechnology
投资方式 Small Core
内部持股比例 4.42%
机构持股比例 96.33%

所有权

姓名 日期 持有股份
Erste Asset Management Gmbh 30 Jun 2025 1,621,415
Voloridge Investment Management, Llc 30 Jun 2025 1,474,155
Aberdeen Group Plc 30 Jun 2025 1,242,404
Bnp Paribas Financial Markets 30 Jun 2025 1,233,749
52周波幅
10.42 (-52%) — 138.81 (526%)
目标价格波幅
5.00 (-77%) — 50.00 (125%)
高 50.00 (BMO Capital, 125.63%) 购买
50.00 (Wells Fargo, 125.63%) 购买
50.00 (Needham, 125.63%) 保留
中 19.50 (-12.00%)
低 5.00 (HC Wainwright & Co., -77.44%) 卖出
平均值 23.00 (3.79%)
总计 6 购买, 12 保留, 4 卖出
平均价格@调整类型 16.78
公司 日期 目标价格 调整类型 价格@调整类型
BMO Capital 22 Sep 2025 50.00 (125.63%) 购买 18.65
29 Jul 2025 50.00 (125.63%) 保留 15.83
Guggenheim 15 Sep 2025 22.00 (-0.72%) 购买 17.47
Leerink Partners 09 Sep 2025 15.00 (-32.31%) 保留 17.64
HC Wainwright & Co. 25 Aug 2025 5.00 (-77.44%) 卖出 18.06
B of A Securities 21 Aug 2025 16.00 (-27.80%) 卖出 20.06
20 Aug 2025 17.00 (-23.29%) 卖出 20.58
Deutsche Bank 15 Aug 2025 12.00 (-45.85%) 卖出 21.81
Goldman Sachs 07 Aug 2025 19.00 (-14.26%) 保留 17.96
Wells Fargo 07 Aug 2025 50.00 (125.63%) 购买 17.96
24 Jul 2025 48.00 (116.61%) 购买 12.88
Barclays 30 Jul 2025 22.00 (-0.72%) 保留 16.75
29 Jul 2025 22.00 (-0.72%) 保留 15.83
Bernstein 29 Jul 2025 13.00 (-41.34%) 保留 15.83
JP Morgan 29 Jul 2025 24.00 (8.30%) 保留 15.83
21 Jul 2025 20.00 (-9.75%) 购买 13.32
Morgan Stanley 29 Jul 2025 20.00 (-9.75%) 保留 15.83
Oppenheimer 29 Jul 2025 37.00 (66.97%) 购买 15.83
18 Jul 2025 41.00 (85.02%) 购买 14.08
Piper Sandler 29 Jul 2025 15.00 (-32.31%) 保留 15.83
22 Jul 2025 11.00 (-50.36%) 保留 13.62
Citigroup 24 Jul 2025 7.00 (-68.41%) 卖出 12.88
Jefferies 24 Jul 2025 35.00 (57.94%) 购买 12.88
Leerink Swann 21 Jul 2025 10.00 (-54.87%) 保留 13.32
Mizuho 21 Jul 2025 14.00 (-36.82%) 保留 13.32
UBS 21 Jul 2025 12.00 (-45.85%) 保留 13.32
Needham 18 Jul 2025 50.00 (125.63%) 保留 14.08
17 Jul 2025 50.00 (125.63%) 购买 21.97
Baird 17 Jul 2025 35.00 (57.94%) 购买 21.97
RBC Capital 17 Jul 2025 23.00 (3.79%) 保留 21.97
显示更多

该时间范围内无数据。

  • 3M
日期 类型 细节
03 Oct 2025 公告 Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress
30 Sep 2025 公告 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Sep 2025 公告 Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year
26 Aug 2025 公告 Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600
25 Aug 2025 公告 Sarepta Therapeutics, Inc. (SRPT) Shareholders Get Answers in Latest SueWallSt Podcast
22 Aug 2025 公告 Latest SueWallSt Podcast: What SRPT Investors Need to Know About the Lawsuit
22 Aug 2025 公告 Investors SueWallSt as Sarepta Therapeutics, Inc. Faces Securities Fraud Allegations
21 Aug 2025 公告 SueWallSt Podcast Series Launches With Focus on Sarepta Therapeutics, Inc. (SRPT) Fraud Allegations
21 Aug 2025 公告 Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027
18 Aug 2025 公告 SueWallSt Podcast Explains Class Action Against Sarepta Therapeutics, Inc. (SRPT)
13 Aug 2025 公告 Shareholders SueWallSt in New Class Action Against Sarepta Therapeutics, Inc. - Act Now
13 Aug 2025 公告 Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment
12 Aug 2025 公告 New SueWallSt Podcast Covers Sarepta Therapeutics, Inc. (SRPT) Class Action
12 Aug 2025 公告 Shareholders SueWallSt in New Class Action Against Sarepta Therapeutics, Inc. - Act Now
06 Aug 2025 公告 Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments
31 Jul 2025 公告 Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results
28 Jul 2025 公告 Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
28 Jul 2025 公告 FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy
25 Jul 2025 公告 Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union
25 Jul 2025 公告 Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
21 Jul 2025 公告 Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.
21 Jul 2025 CNBC FDA taps biotech industry veteran as RFK Jr.'s top drug regulator 
18 Jul 2025 公告 Sarepta Therapeutics Provides Statement on ELEVIDYS
18 Jul 2025 CNBC Sarepta shares plunge 40% as future of its gene therapy appears at risk
16 Jul 2025 公告 Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票